UMass Medical School researchers helped to develop a new tool that may predict a person’s chance of survival after a gunshot wound or other penetrating brain injury. Susanne Muehlschlegel, MD, MPH, is lead author on the study published online in the journal Neurology.
Merck has announced that the U.S. FDA has approved Zinplava™ to reduce recurrence of C. diff infection. The drug was developed by researchers at MassBiologics in conjunction with Medarex (now part of Bristol-Myers Squibb), and licensed to Merck in 2009.
UMass Medical School scientist and internationally recognized amyotrophic lateral sclerosis (ALS) researcher Robert H. Brown Jr., DPhil, MD, said he believes a breakthrough is within reach and explained his motivation in working to find it.
Academia is connecting with industry in a unique, new collaboration called the UMass Metabolic Network, in which scientists at UMass Medical School in Worcester will meet monthly to exchange ideas with peers from Pfizer in Cambridge.
In collaboration with four regional medical center groups, UMass Medical School will help to implement a prestigious precision medicine program aimed at individualizing disease prevention and treatment, according to the National Institutes of Health.
Celia Schiffer, PhD, has been selected by the Massachusetts Society for Medical Research as the recipient of the 2016 Mentoring Award for excellence in mentoring of STEM trainees. She will be recognized at the Society’s annual Biomedical Research Day Honors program on Oct. 21.
The Massachusetts High-Resolution Cryo-Electron Microscopy Facility opened at UMass Medical School on Tuesday, Oct. 4. The cryo-EM research core is New England’s first installation of the transformative technology.
UMMS scientists, led by Allan Jacobson, PhD, have uncovered a new mechanistic understanding of potential treatment for genetic disorders.
UMass Medical School physician-scientist Kevin Donahue, MD, is running two federally funded studies of gene therapy for atrial fibrillation.
UMass Medical School cancer researcher Wen Xue, PhD, accepted a $250,000 grant Friday from the Hyundai Motor America Hope on Wheels campaign to continue his work toward improving care and treatment options for children with cancer.